Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02259413
Other study ID # B2014:088
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2015
Est. completion date June 8, 2023

Study information

Verified date June 2023
Source University of Manitoba
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether participation in a 26-week exercise rehabilitation program is effective at reducing symptom burden and improving quality of life in individuals receiving chronic hemodialysis.


Description:

Individuals with end-stage kidney disease requiring HD suffer from multiple symptoms, which have limited effective treatments. Symptom burden, the combined impact of number and severity of symptoms, negatively impacts functional status and health-related quality of life (HRQOL) in HD. Small interventional trials suggest exercise can mitigate specific individual symptoms, but impact of exercise on overall symptom burden in HD is unknown. Dialysis patients have identified improving symptom burden and HRQOL as research priorities. We propose the first randomized controlled trial (RCT) investigating the effect of exercise rehabilitation on symptom burden in individuals on HD. Hypothesis: In individuals on HD, participation in a 26-week exercise rehabilitation (rehab) program will reduce symptom burden and improve HRQOL, resulting in reduced disability and improved long-term clinical outcomes as compared with standard care. Study Design: Single-centre RCT with one-to-one parallel design, allocation concealment and assessor blinding Study Population: Adults receiving chronic in-centre HD for > 3 months with at least one dialysis-related symptom; n=150 Intervention: Standard care plus 26-week structured rehab program (lifestyle education, resistance exercise and cycling during HD). Control: Standard care (baseline exercise counseling) Outcomes measured at baseline, 12, 26 and 52 weeks. Data Analysis: Will be performed on an intention to treat, available case basis with t-tests or Mann Whitney U for continuous outcomes, as per data distribution and Chi square tests for categorical outcomes. Mixed effects modeling will account for repeated outcome measures over time. Poisson regression will be performed for hospitalization analysis. Anticipated Outcomes: Mean symptom burden severity score will decrease by 20% from baseline in the intervention group at 12 weeks. Due to sustained physical activity in the intervention group, symptom burden will remain lower in this group at 6 months. In contrast, the control group will see no improvement in symptom burden from baseline.


Recruitment information / eligibility

Status Completed
Enrollment 133
Est. completion date June 8, 2023
Est. primary completion date June 8, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - greater than 3 months after starting chronic hemodialysis - no planned change in hemodialysis modality or relocation outside of Winnipeg during study intervention period (26 weeks) - assessed to be safe and able to exercise by HD unit nephrologist - ability to communicate in English and provide informed written consent Exclusion Criteria: - acute coronary syndrome in past 3 months - unstable arrhythmia - shortness of breath at rest or with minimal activity (NYHA Class 4) - symptomatic hypoglycaemia (> 2x/week in week prior to enrolment) - currently participating in the Manitoba Renal Program clinical intradialytic cycling program - score of 0 on Dialysis Symptom Index when administered at time of consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise Rehabilitation
This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks

Locations

Country Name City State
Canada Health Sciences Centre Winnipeg Manitoba
Canada Seven Oaks General Hospital Winnipeg Manitoba
Canada St. Boniface Hospital Winnipeg Manitoba

Sponsors (2)

Lead Sponsor Collaborator
University of Manitoba The Wellness Institute at Seven Oaks General Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in physical activity behaviour pattern Measured in 2 ways:
Subjectively using the self-reported Godin-Shephard Leisure Time Physical Activity Questionnaire
Objectively using multi-directional accelerometers (Actical Physical Activity Monitors TM) which will be worn for 7 days at each measurement time point
2.
Measured at study baseline, 12, 26 and 52 weeks after study start
Other Hospitalization rate Measured by number of hospitalizations and length of stay for each hospitalization Measured at study baseline, 12, 26 and 52 weeks after study start
Other Mortality Measured as the proportion of people who died during the first year on dialysis Measured at 1 year after starting dialysis
Primary Change in dialysis symptom burden at 12 weeks Measured using change in the Dialysis Symptom Index Measured at study baseline and 12 weeks after study start
Secondary Change in dialysis symptom burden at 26 and 52 weeks Measured using change in the Dialysis Symptom Index Measured at study baseline, 26 and 52 weeks after study start
Secondary Change in modified symptom burden Measured using change in modified Dialysis Symptom Index Measured at study baseline, 12, 26 and 52 weeks after study start
Secondary Change in health-related quality of life Measured by self-report using the EuroQol 5D-5L (EQ5D-5L) and EuroQol Visual Analogue Scale. Measured at study baseline, 12, 26 and 52 weeks after study start
Secondary Change in time for recovery post-dialysis Measured in minutes with the question "Approximately how much time does it take to recover from a dialysis session" Measured at study baseline, 12, 26 and 52 weeks after study start
Secondary Change in endurance/exercise capacity Measured using the Incremental Shuttle Walk Test Measured at study baseline, 12, 26 and 52 weeks after study start
Secondary Change in frailty status Measured using the Modified Fried Criteria for frailty. Measured at study baseline, 12, 26 and 52 weeks after study start
Secondary Change in self-efficacy for exercise Measured using the Self-Efficacy for Exercise Survey a 9 item self-reported assessment tool Measured at study baseline, 12, 26 and 52 weeks after study start
See also
  Status Clinical Trial Phase
Completed NCT04087213 - Study of HemoCareā„¢ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD N/A
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT02237521 - The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease N/A
Withdrawn NCT01691196 - Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
Completed NCT01394341 - Liraglutide Treatment to Patients With Severe Renal Insufficiency Phase 4
Active, not recruiting NCT00247507 - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Phase 4
Completed NCT00307463 - Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Phase 4
Recruiting NCT00155363 - Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis Phase 4
Completed NCT00234156 - The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers N/A
Completed NCT00586131 - Arterial pH and Total Body Nitrogen Balances in APD Phase 4
Active, not recruiting NCT05027074 - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Phase 2
Recruiting NCT04575077 - The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
Enrolling by invitation NCT05001009 - Goals of Care Conversations Study N/A
Completed NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury Phase 2
Recruiting NCT03862859 - The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis Phase 4
Terminated NCT03661229 - Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device N/A
Completed NCT03288922 - Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF N/A
Completed NCT02360748 - A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients N/A
Completed NCT02572882 - Gut Microbiome and p-Inulin in Hemodialysis N/A